RECRUITINGINTERVENTIONAL

Functional Pulmonary Capillary Surface Area in BPA for CTEPH

Assessment of Recovery of Functional Capillary Surface Area in Patients Undergoing a Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension

About This Trial

Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.

Who May Be Eligible (Plain English)

Who May Qualify: - All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension Who Should NOT Join This Trial: - Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, - Presence of patent foramen ovale Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension Exclusion Criteria: * Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, * Presence of patent foramen ovale

Treatments Being Tested

OTHER

Measurement of pulmonary functional capillary surface area

Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro

Locations (1)

David Langleben

Montreal, Quebec, Canada